FDA's Shocking Approval: Rexulti Fast-Tracked Despite Deadly Risks

Investigation raises serious questions about the harm-benefit balance of Rexulti; the Decision may reverse efforts to reduce the use of antipsychotics in US care homes. During testing, the antipsychotic medication brexpiprazole (Rexulti) did not demonstrate a significant therapeutic effect and was

FDA rushes approval of dementia drug that quadruples risk of death

Low-Dose Tramadol as an Off-Label Antidepressant: A Data Mining

FDA advisers back Lundbeck and Otsuka's Rexulti in Alzheimer's

FDA Faces Hard Decisions After Fast-Tracking Unproven Drugs

FDA's Shocking Approval: Rexulti Fast-Tracked Despite Deadly Risks

FDA's accelerated drug approvals often lack confirmatory evidence

How the FDA approved an antipsychotic that failed to show a

FDA Approves Rexulti for Agitation Associated With Dementia Due to

Not Everyone Agreed With FDA Approval of Antipsychotic Rexulti for

U.S. FDA Approved Drugs from 2015–June 2020: A Perspective

WD - June/July 2022 by Lawrence Ambrocio - Issuu

Otsuka and Lundbeck Issue Statement on U.S. Food and Drug

SEC Filing Vistagen Therapeutics, Inc

FDA Fast Tracked Drugs Make Companies Billions on Unproven Claims

Drugs News - Page 2 of 15 - SciTechDaily